RavenQuest BioMed Inc (CNSX:RQB) (OTCMKTS:RVVQF) (FRA:1IT) CEO George Robinson joins Midas Letter to discuss the company’s ‘Orbital Gardens‘ and the advantages of using the rotational growth technology on a large scale. The RavenQuest Orbital Garden allows for production of large quantities of cannabis in smaller areas by maximizing the productivity of grow space and lighting. The technology is able to produce over 300 Grams per square foot – which is currently double the industry averages. The company is also expanding into the European medical marijuana sector, recently completing a joint venture agreement to construct cannabis production facilities using RavenQuest’s Orbital Garden grow technology. It is anticipated that production facilities will produce up to 35,000 kilograms of cannabis annually by 2021. The CEO also outline the company’s road to profitability, surmising EBITDA rates of between 38 to 42 percent and profitability by the end of calendar year 2019.

Original article: RavenQuest BioMed Inc (CNSX:RQB) Expanding Industry Disruptive Growing Technology©2019 Midas Letter. All Rights Reserved.

Halo Labs Inc (NEO:HALO) (OTCMKTS:AGEEF)  (FRA:A9KN) CEO Kiran Sidhu joins James West from The Wine Academy to detail the release of the Shatterizer. The portable device is the first custom vapourizer made for the DabTab Dablets allowing consumers to experience flavourful concentrates, waxes, live resin, distillates and many other forms of cannabis extracts in a precise doseable format. The CEO outlines the differences between all the varieties of cannabis extracts and the anticipated uptake from customers in the US cannabis market. The rollout sold out Halo’s initial inventory of the portable vapourizer device. The Company has launched the initial rollout of the Shatterizer in Oregon, selling the product in 30 accounts with expectation to reach more in the near-future.

 

**IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**

Notice for Forward-Looking Information

Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such forward-looking information includes that HALO Labs Inc will be a big, successful company in the cannabis sector; that cannabis use and sales will grow and HALO’s sales along with it; HALO’s intended acquisition of various foreign companies and expansion into the US market; that extraction is and will continue to be a fast growing and profitable sector of the cannabis industry; that HALO will reach $48M in revenues in 2019; HALO’s plans to produce concentrates and sell them in various locations throughout the world; that HALO could be granted licenses to expand; and that it will be able to carry out its business plans.

Readers are cautioned to not place undue reliance on forward-looking information. Forward looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on HALO. Such risks and uncertainties include, among other things: that a regulatory approval that may be required for the intended acquisitions and subsequent sales are not obtained or are obtained subject to conditions that are not anticipated; growing competition for intended acquisitions in the cannabis industry; potential future competition in the markets HALO operates for sales; competitors may quickly enter the industry; general economic conditions in the US, Canada and globally; the inability to secure financing necessary to carry out its business plans; competition for, among other things, capital and skilled personnel; the possibility that government policies or laws may not permit legal cannabis sales or growth or that favorable laws in place may change; HALO not adequately protecting its intellectual property; interruption or failure of information technology systems; the cannabis market may not grow as expected; HALO’s technology may not achieve the expected results and its accomplishments may be limited; even if it is granted patents, it may not have success at licensing its technologies or sell its products at the rate expected; planned acquisitions and partnerships may not materialize because of inability to agree on terms with prospective partners or targets; HALO’s business plan also carries risk, including its ability to comply with all applicable governmental regulations in a highly regulated business; incubator risk investing in target companies or projects which have limited or no operating history and are engaged in a

Valens Groworks Corp (TSX-V:VGW) (OTCMKTS:MYMSF) (FRA:7LV) President Jeffrey Fallows highlights company milestones achieved in the second quarter of 2019. Among increasing revenues 296 percent from the previous quarter, Valens also anticipates operating to almost full capacity  in terms of volumes by end of the calendar year. To keep in front of the growing demand, Valens have recently announced a large-scale capacity increase to 425,000 kilograms per year – making Valens the largest third party extraction facility in Canada. The Valens President also discusses helping the company with its future international expansion.

Transcript

Narrator:  Valens GroWorks Corp. is a multi-licensed, vertically-integrated cannabis company focused on being the partner of choice for leading Canadian and international cannabis brands.

Valens is the largest third-party extraction Company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at their purpose-built facility in Kelowna, British Columbia.

Additionally, their subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical service

Valens GroWorks Corp trades on the TSX-Venture under the ticker VGW

James West: I’m joined now by Jeffrey Fallows. He’s the President of Valens GroWorks Corp., trading on the TSX Venture under the symbol VGW. Jeffrey, welcome.

Jeffrey Fallows: Thanks for having me.

James West: Tell me about all that is happening in Valens Gro recently.

Jeffrey Fallows: So we just announced our second quarter 2019, and had some pretty strong results coming out of there, plus there’s a lot of volumes and really starting to hit up our ramp in terms of both revenue and EBITDA. So, really starting to hit our stride, and really looking forward to things coming in the next couple of quarters.

James West: Yeah, wow, that’s quite an increase – up 296 percent in the first quarter over last year’s first quarter. What’s the annual run rate looking like for exit 2019?

Jeffrey Fallows: So we’re seeing a pretty steady increase in volumes as the year goes on. We anticipate being pretty close to our full capacity by the end of the year in terms of volumes through. Right now, we’re really working with our partners in ensuring, you know, there’s a lot of process that goes in with the scale-up both on their side and our side, making sure volumes come in where they’re supposed to come in and go out where they’re supposed to go out.

James West: Right.

Jeffrey Fallows: So, making great progress on that, and every day it’s getting better, as you can see with the quarter-over-quarter volume increase.

James West: You bet. So I recall that Valens GroWorks was making sequential announcements that you were extracting for this large-scale LP, that large scale LP, but you also had some of your own cultivation. Is that still the mix?

Jeffrey Fallows: So we are not doing any cultivation.

James West: Oh, okay.

Jeffrey Fallows: We are focused exclusively on providing extraction services to our clients, and as we’ve also announced, we’re now moving from straight base extraction, where we provide either crude or distillate oils to our customers; we’re also now moving to Phase II in the market, which is, you know, vape pens, softgels, topicals, all those kind of sort of next-generation products that are going to hit the shelves later this year.

James West: Oh, okay, so you’re doing all of the products. Do you have a focus, do you have a product line into the medical world, as well?

Jeffrey Fallows: Yeah, we are, whether it’s recreational or medical, we’re agnostic as to which market it goes into. We’re about providing good quality products to our customers.

James West: Sure. So does that mean you are going to source your feedstock biomass all the time from LPs?

Jeffrey Fallows: Yeah. So a majority of our volumes right now are processed through toll, which means that they remain the property of the LPs. We send b

Heritage Cannabis Holdings Corp (CSE:CANN)(OTCQX: HERTF) CEO Clint Sharples sits down to discuss the most recent company development, acquiring 30% of Endocanna Health. Endocanna has developed an Endocannabinoid DNA test which uses a home- based saliva collection kit to identify which cannabinoids align with your particular DNA. The process was developed to assist people in making conscious health choices, and informed decisions on formulations and dosing of cannabinoids.

Transcript

Narrator: Heritage Cannabis Holdings, Corp., operates a holding company which cultivates, sells and distributes medical cannabis in Canada.

The company currently has two Health Canada-approved licensed producers through its subsidiaries, PhyeinMed, Inc. and Cannacure Corp., both of which are regulated under the Cannabis Act regulations.

Heritage Cannabis is focused on advancing its scale and technology footprint to compete both domestically and internationally.

Heritage Cannabis Holdings, Corp. trades on the CSE under the ticker symbol CANN.

James West: Clint Sharples joins me now. He’s the President and CEO of Heritage Cannabis Holdings Corp., on the CSE trading under symbol CANN. Clint, welcome back.

Clint Sharples: I didn’t know today was wearing your best jacket day; I should have done something better than this. I’m feeling bad.

James West: No, that’s okay, Clint. You know, this is a hard act to follow in the jacket department.

Clint Sharples: Looking good.

James West: Thank you. Clint, you guys are in the midst of a transaction that will see you acquire a portion of ownership of this company, Endocanna Health. Tell me about the transaction, and tell me about Endocanna Health, please.

Clint Sharples: Yeah. We’re, as I mentioned before when we were here talking about this about a month and a half ago, when we did our agreement with them, we’ll be closing this deal at the end of next week. We’re purchasing 30 percent of Endocanna. Being a DNA test kit, very similar to 23AndMe or a Ancestry DNA, you do the swab in your mouth, you put it into the jar, shake it up and send it in.

What it allows you to do is, it takes your information, your genetics, and matches you with the cannabinoids and the strains, sometimes, that can best match you and your genetic profile. What that allows you to do is find out which cannabinoid is most effective for you, and your makeup. So if you’re going to find some sleep meds, find the ones that match best with whatever your situation is, and those should work best for you, and should provide a safer environment for you to use cannabis.

James West: I see. So can this be used recreationally to find the cannabis that doesn’t make you catatonic and paranoid, and instead makes you happy, high and giddy?

Clint Sharples: I’m sure you could use it for that, although it is mostly geared towards the medical aspect, because they have doctors on staff that can additionally help with the information provided. That’ll really allow you to get a personalized cannabis medical profile.

James West: Hmm, interesting. So, how much does the test cost for an individual?

Clint Sharples: Right now, their test is $200 USD, which does the full gamut. They send you this kit that you see here today, and then they’ll send you your report. However, if you do happen to have 23AndMe or Ancestry DNA, you can take those results and upload it into their website, their algorithm they have, and it’ll give you the exact same information. I can’t remember what that cost is, but it’s lower than going with the kit.

James West: Okay, interesting. So then, is the benefit to Heritage the idea that these guys might recommend some cannabis or products that you guys produce?

Clint Sharples: Absolutely. Yeah. Endocanna is what we would consider to be the first step in the medical process of taking true control over how cannabis interacts with your medical profile. So Endocanna can be a great introduction and a great information source for Heritage that will lead us

Khiron Life Sciences Corp (CVE:KHRN) (OTCMKTS:KHRNF) (FRA:4KH) consumer brand Kuida Cosmeceuticals was present at the FounderMade event in New York City earlier this month. FounderMade organizes various conferences used to discover and scale for consumer brands and retailers. FounderMade helps consumer brands expand their businesses and launch innovative products through their Discovery Show, invite-only CEO Summit, and membership program. Elsa Navarro, the Skin Unit Manager for Khiron Life Sciences joins Fraser Toms to discuss the turnout and feedback.

Transcript

Narrator: Kuida Cosmeceuticals, the first consumer brand of Khiron’s wellness business unit, brings the benefit of CBD to a comprehensive portfolio of skin care products, both face and body care products for women.

Kuida uses a technology developed specially for skin care based on the synergy of its active ingredients and cannabis, naturally boosting the antioxidant action; this is called CBDerm.

Khiron is the first brand in Colombia to develop cosmeceutical products based on the benefits of CBD. Khiron trades on the TSX Venture under the symbol KHRN.

Fraser Toms: Hi. We’re joined by Elsa Navarro, who is the Skin Unit Manager for Khiron Life Sciences. Elsa, how are you?

Elsa Navarro: Fine, very well. Thank you so much for having me again.

Fraser Toms: Yeah, no problem. Great. So we understand that you guys attended the Founder Made event. Can you give us an idea what that was all about?

Elsa Navarro: Well, Founder Made is a really VIP event. It took place last week in New York City, and it’s a perfect opportunity to showcase new brands to specific retailers, media and influencers only. So it was a great opportunity for showcasing Kuida for the US market.

Fraser Toms: What do you feel is presenting a brand at an event like that? Are you kind of unique in the space?

Elsa Navarro: It’s a great opportunity to realize that we’re going from local to global and that we’re really creating competitive brands here in Khiron. It was amazing for us in such a competitive landscape as it is, Founder Made, to see that our products have a completely different story from other CBD-based products. We’re a complete-range brand, and our quality, our packaging, were really appealing to the decision-makers.

Fraser Toms:What about the kind of feedback you were getting at the event? Tell us what kind of stood out to you, and how people seemed to receive the brand?

Elsa Navarro: It was really exciting for us to get the feedback. Buyers, influencers, were amazed, first because of the branding; we were telling the story, then when we’re teaching people the texture, that we are really competitive with any other cosmetic brand. And as well, our explaining about CBD and our CBD technology that really explains how CBD is competitive and an active ingredient that has a lot of potential for the future.

Fraser Toms: Yeah. And Founder Made was in New York City, obviously, and so the relationship with Dixie Brands being a US company, how does that impact the presentation?

Elsa Navarro: I think this was the perfect opportunity to start our joint venture. As you know, we have a 50/50 joint venture with Dixie; they have really great relationship with retailers, but this was the first opportunity to work together as a team and to be able to showcase our products to this 20 billion million market in the US when we’re talking about cosmetics.

Fraser Toms:Yeah. So if I were to drive down south of the border now, would I be able to pick up some Kuida products yet?

Elsa Navarro: Well, really soon. We’re hoping to be there at the end of this year; we’re pending the TSX approval, we’re working on that. But for sure by the end of this year, we’ll be in the first retailers in the United States..

Fraser Toms: Okay, great. And so that sounds like a good timeline. When was the product launched, just to see how far we’ve come?

Elsa Navarro: We launched Kuida here in Colombia last October. We were on shelves in Novemb

Next Green Wave Holding Inc (CSE: NGW) (OTCQX: NXGWF) is a California-based extractor and Consumer Packaged Goods producer. The company’s CEO, Leigh Hughes, joins James to give me an overview of how the company operates in the California market and details Next Green Wave’s premium angle on almost every aspect of that business. Next Green Wave has eight cannabis brands, with 45 different product SKU’s, encompassing a wide-array of cultures that exist in cannabis within California. The company is also using using premium influences coupled with its differentiated product catalogue, which plays a significant role in the company’s premium marketplace strategy.

Original article: Next Green Wave Holdings (CNSX:NGW) Premium Angle on Californian Cannabis Market©2019 Midas Letter. All Rights Reserved.

Renowned Canadian entrepreneur Joseph Mimran joins James West to discuss his strategic counsel to Khiron Life Sciences Corp (CVE:KHRN) (OTCMKTS:KHRNF) (FRA:4KH). While Mr. Mimran is internationally recognized as a brand and retail concept visionary known for iconic brands such as Joe Fresh and Club Monaco, he also provides Khiron with expertise on packaged goods and retail development for the Latin American market. The Moroccan-Canadian entrepreneur adds tremendous value to Khiron’s already experienced management team and Board of Directors with a proven record in brand development and will help distinguish Khiron’s products from the competition. The Dragon from CBC’s Dragons’ Den believes Khiron “are sitting on so much potential” having first-mover advantage in the multi-billion global market in Latin America and is excited by the talent the company has attracted as well as the expanding Kuida product lines and distribution.

 

**IMPORTANT! BY VIEWING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**

Notice for Forward-Looking Information

Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such forward-looking information includes that Khiron Life Sciences Corp will be a big, successful company in the cannabis sector; that cannabis use and sales will grow and KHIRON’s sales along with it; KHIRON’s intended acquisition of various foreign companies and expansion into the European and South and North American markets; that cosmeceuticals is and will continue to be a fast growing and profitable sector of the cannabis industry; and that it will be able to carry out its business plans.

 

Readers are cautioned to not place undue reliance on forward-looking information. Forward looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on KHIRON. Such risks and uncertainties include, among other things: that a regulatory approval that may be required for the intended acquisitions and subsequent sales are not obtained or are obtained subject to conditions that are not anticipated; growing competition for intended acquisitions in the cannabis industry; potential future competition in the markets KHIRON operates for sales; competitors may quickly enter the industry; general economic conditions in the US, Canada and globally; the inability to secure financing necessary to carry out its business plans; competition for, among other things, capital and skilled personnel; the possibility that government policies or laws may not permit legal cannabis sales or growth or that favorable laws in place may change; KHIRON not adequately protecting its intellectual property; interruption or failure of information technology systems; the cannabis market may not grow as expected; KHIRON’s technology may not achieve the expected results and its accomplishments may be limited; even if it is granted patents, it may not have success at licensing its technologies or sell its products at the rate expected; planned acquisitions and partnerships may not materialize because of inability to agree on terms with prospective partners or targets; KHIRON’s business plan also carries risk, including its ability to comply with all applicable governmental regulations in a highly regulated business; incubator risk investing in target companies or proj

Shatterizer Inc Co-founder Valerie McCulloch joins James West in Los Angeles, California to roll-out the Shatterizer DabTabs edition portable vaporizer. Watch the pair explore and demo the revolutionary cannabis extract products while explaining the specifics around dabbing, shatter, and how concentrates makes up a significant portion of the North American marijuana market. 

As concentrates are the most potent and premium product derivatives of the cannabis plant, consumers need to be assured of consistency and flavour profile with each dose. The Shatterizer, using a borosilicate glass globe, brings that reliability to a premium vape pen – while remaining elegant and portable. Working in conjunction with Shatterizer, DabTabs provides consumers with the ability to prefill DabTabs Tablets with measured doses of either cannabis or cannabidiol. DabTab Dablets are expected to generate distribution throughout Canada, the United States and Europe.

Halo Labs Inc (NEO:HALO) (OTCMKTS:AGEEF)  (FRA:A9KN) has the exclusive rights to the DabTabs products in Nevada and California, providing the Company with a unique position in capturing a large portion of the market. These innovative products are changing the way that dabbing is experienced by consumers, creating a cleaner and easier experience than traditional dabbing. The shatterizer is the newest form of vaporizers that allows consumers to experience smooth, flavourful use of a variety of concentrates, dabs, waxes, resin, and many other forms of extracts portably.

 

**IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**

Notice for Forward-Looking Information

Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such forward-looking information includes that HALO Labs Inc will be a big, successful company in the cannabis sector; that cannabis use and sales will grow and HALO’s sales along with it; HALO’s intended acquisition of various foreign companies and expansion into the US market; that extraction is and will continue to be a fast growing and profitable sector of the cannabis industry; that HALO will reach $48M in revenues in 2019; HALO’s plans to produce concentrates and sell them in various locations throughout the world; that HALO could be granted licenses to expand; and that it will be able to carry out its business plans.

Readers are cautioned to not place undue reliance on forward-looking information. Forward looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on HALO. Such risks and uncertainties include, among other things: that a regulatory approval that may be required for the intended acquisitions and subsequent sales are not obtained or are obtained subject to conditions that are not anticipated; growing competition for intended acquisitions in the cannabis industry; potential future competition in the markets HALO operates for sales; competitors may quickly enter the industry; general economic conditions in the US, Canada and globally; the inability to secure financing necessary to carry out its business plans; competition for, among other things, capital and skilled personnel; the possibility that government policies or laws may not permit legal cannabis sales or growth or that favorable laws in place may change; HALO not adequately protecting its i

Chris Naprawa, the President of Khiron Life Sciences Corp (CVE:KHRN) (OTCMKTS:KHRNF) (FRA:4KH), visited Midas Letter to address the internet rumours speculating that the company has not registered its seeds with the Colombian regulators when, in contrast, Khiron has five separate strains registered at this moment with further strains soon to start the process. While misguided rumours circulate online, Khiron is still the dominant integrated cannabis company in Colombia. The company’s potential addressable patient network is over 1 million individuals represented by over 5,000 doctors through six medical association endorsements. Khiron’s Wellness line, Kuida, also has distribution agreements with the largest retail outlets throughout Colombia, with over 176 points of sale. The Khiron President is not focused on the summer doldrum market selloff and is concentrating his efforts towards the company’s patients and consumers by executing on growing the business.

Original article: Khiron Life Sciences Corp (CVE:KHRN) Only Revenue Generating Colombian LP©2019 Midas Letter. All Rights Reserved.

Martello Technologies Group Inc (TSXV: MTLO) CEO John Proctor joins James West to discuss the company’s recent stock surge. The catalyst for the exponential movement has come off-the-back of the shock news of Canopy Growth Corp (TSE:WEED) (NYSE:CGC) (FRA:11L1) announcing a leadership transition to replace Bruce Linton as CEO. Investors have been galvanized since finding out Bruce Linton, co-chairman of Martello, will have more time to dedicate to the technology company. Mr Proctor outlined that “Bruce has always been involved” but with his departure from Canopy “he has more time for us.” The CEO also discusses the company’s financials and highlights past and future acquisitions which will help take the company into the realm of a multi-billion-dollar global operator.

Original article: Bruce Linton Dedicating More Time to Martello Technologies Group Inc (CVE:MTLO)©2019 Midas Letter. All Rights Reserved.